PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

ME Staff 8-k

6 years ago

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On May 21, 2019, the Board of Directors of Puma Biotechnology, Inc. (the Company) approved the Companys Third Amended and Restated Bylaws (the Amended Bylaws) in connection with permitting stockholders who hold, in the aggregate, at least 25% of the voting power of the outstanding shares of the Company to call a special meeting of stockholders, subject to the limitations and requirements set forth in the Amended Bylaws. The Amended Bylaws also provide the Board with discretion to determine that a stockholder meeting may be held via remote communication, as well as incorporate various conforming, ministerial and other related changes.

A copy of the Amended Bylaws is filed as Exhibit 3.1 to this current report on Form 8-K and is incorporated herein by reference. A copy of the Amended Bylaws, marked to show the amendments reflected in the Amended Bylaws as compared to the Companys prior bylaws, is also attached as Exhibit 3.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

PUMA BIOTECHNOLOGY, INC. Exhibit
EX-3.1 2 d756564dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF PUMA BIOTECHNOLOGY,…
To view the full exhibit click here

About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.